

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

INTERLEUKIN GENETICS INC
Form 8-K
August 05, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): AUGUST 5, 2002

INTERLEUKIN GENETICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other
jurisdiction of
incorporation)

000-23413

(Commission
File Number)

94-3123681

(IRS Employer
Identification No.)

135 BEAVER STREET, WALTHAM, MA 02452

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 398-0700

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

On August 5, 2002, Interleukin Genetics, Inc. (the "Company"), upon the approval of its Audit Committee, engaged Grant Thornton LLP ("Grant Thornton") to serve as the Company's independent public accountants for the fiscal year ending

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

December 31, 2002.

During the fiscal years ended December 31, 2001 and 2000 and through August 5, 2002, the Company did not consult Grant Thornton with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matters or reportable events listed in Items 304(a)(2)(i) and (ii) of Regulation S-K.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERLEUKIN GENETICS, INC.

(Registrant)

Date: August 5, 2002

/s/ Fenel M. Eloi

Fenel M. Eloi, Vice President,
Chief Operating Officer and Chief
Financial Officer

3